GlassScriptPhysician profile
Yong Luo
NPI 1902130628
$11,102.86
in general payments reported to CMS, 2019-2025
30 companies · $4,014 in 2025
The $4,014 reported for 2025 was more than what 84% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $759 · 2021: $783 · 2022: $1,103 · 2023: $2,150 · 2024: $1,823 · 2025: $4,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,707 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,706.89 |
| Education | $279.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,550.84 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,735.51 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $1,375.48 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,009.98 | 2020-2025 | Airsupra, Fasenra, Breztri |
| Amgen INC. | $424.15 | 2020-2025 | Tezspire |
| Axsome Therapeutics, INC. | $375.00 | 2023-2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $369.41 | 2022-2025 | |
| Grifols USA, LLC | $345.42 | 2023-2025 | Xembify |
| Teva Pharmaceuticals USA, INC. | $304.09 | 2019-2023 | Austedo Xr |
| Neurocrine Biosciences, INC. | $248.68 | 2021-2025 | |
| Optinose US, INC. | $238.36 | 2019-2020 | |
| Insmed, INC. | $146.40 | 2025 | Brinsupri |
| Novartis Pharmaceuticals Corporation | $142.90 | 2025 | |
| Idorsia Pharmaceuticals US INC | $120.74 | 2023 | Quviviq |
| Leo Pharma INC. | $104.06 | 2023-2024 | Adbry |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $96.38 | 2019 | |
| Merck Sharp & Dohme LLC | $89.28 | 2021-2023 | |
| Lilly USA, LLC | $67.72 | 2024-2025 | Ebglyss |
| Alk-Abello, INC | $63.92 | 2019-2022 | |
| Aerin Medical INC. | $50.28 | 2024 | |
| Incyte Corporation | $44.77 | 2024-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $41.89 | 2025 | Zoryve |
| Genentech USA, INC. | $24.58 | 2024 | Xolair |
| Verona Pharma, INC. | $22.79 | 2025 | Ohtuvayre |
| Pfizer INC. | $21.43 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $19.64 | 2025 | Neffy |
| Abbvie INC. | $18.17 | 2022 | |
| Aytu Biopharma, INC. | $17.91 | 2024 | Karbinal |
| Circassia INC. | $17.40 | 2019 | |
| Galderma Laboratories, L.P. | $15.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yong Luo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.